Advocacy intelligence hub — real-time data for patient organizations
Ohio State University Comprehensive Cancer Center — PHASE1
Fred Hutchinson Cancer Center — PHASE1, PHASE2
University of Utah — PHASE1
Memorial Sloan Kettering Cancer Center — PHASE2
Memorial Sloan Kettering Cancer Center — PHASE3
Abramson Cancer Center at Penn Medicine — PHASE2
University of Washington — PHASE2
Mayo Clinic — PHASE2
Shanghai YingLi Pharmaceutical Co. Ltd. — PHASE4
H. Lee Moffitt Cancer Center and Research Institute — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Bendeka
Eagle Pharmaceuticals, Inc.
Zevalin
(ibritumomab tiuxetan)Orphan drugAcrotech Biopharma LLC
12.1 Mechanism of Action Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). Th...
Bendeka
(bendamustine for 50 ml admixture)Orphan drugstandardEagle Pharmaceuticals, Inc.
12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and it...
Treanda
(Bendamustine hydrochloride)Orphan drugstandardCephalon, Inc.
12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and it...
Ajay Gopal
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Mengyang Di, MD, PhD, MD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Ajay K. Gopal
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Mathias Rummel, Dr
University of Giessen
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Jonathon B Cohen, MD, MS, M.D
Emory University
📍 ATLANTA, GA